RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie's acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. It further told investors in a research note that the deal brings a significantly more commercially capable operator with deep dermatology market relationships and decades of experience selling Humira and Skyrizi behind Zumi, which is Apogee's long-acting IL-13 antibody in atopic dermatitis, and a potential next-gen competitor to Dupixent.

In a separate development, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on May 28 that maftivimab has been recommended by the World Health Organization's (WHO) Therapeutics Advisory Group to be prioritized for evaluation in clinical trials of investigational treatments for Bundibugyo ebolavirus. Maftivimab is the most potent neutralizing antibody included in Inmazeb®, according to the company, and has exhibited broad activity in vitro against multiple Ebola spe

Fuente original: Yahoo Finance (https://finance.yahoo.com/markets/stocks/articles/rbc-capital-maintains-sector-perform-140119882.html)